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 Honey bee viruses, capable of causing a wide variety of detrimental effects, are an 
important dimension of honey bee health management. To date, there are no effective treatments 
for viral infection in honey bees and management relies largely on controlling Varroa mites, a 
honey bee pest capable of vectoring viruses. Plant-derived chemicals (phytochemicals) represent 
a broad range of substances that honey bees frequently encounter and consume, many of which 
are known to improve honey bee health, although their effect on bee viruses is largely unknown. 
This thesis project tested the therapeutic effectiveness of various phytochemicals on viral 
infection by measuring their ability to improve survivorship in honey bees inoculated with Israeli 
acute paralysis virus (IAPV).  
 In the absence of a viable cell line, virus particles were generated, purified, and extracted 
from honey bee pupae by pairing established protocols with “larval crawl-outs” a novel method 
of pupal extraction that greatly improved the efficiency of particle production. In the first part of 
this project, I screened for phytochemical effects by first inoculating honey bees with viral 
particles and then feeding them thymol, carvacrol, p-coumaric acid, quercetin, or caffeine in a 
series of high-throughput bioassays, all of which were chosen based on their immune-boosting 
properties in honey bees. Among these candidates, caffeine was the only phytochemical capable 
of significantly improving survivorship and was therefore selected for additional testing. 
 Initial screening showed that naturally-occurring concentrations of caffeine (25 ppm) 
were sufficient to produce an ameliorative effect on IAPV infection. Consequently, the second 
half of this project focused on determining the scope of caffeine effectiveness in bees inoculated 
and uninoculated with IAPV by performing the same type of high-throughput bioassay across a 
wider range of caffeine concentrations. My results indicated that caffeine may provide benefits 
that scale with concentration, to a point, and may partially compensate for seasonal nutritional 
deficits within a colony. However, the exact mechanism by which caffeine ingestion improves 
survivorship remains uncertain, as a comparison of viral titers between inoculated and 
uninoculated caffeine-fed bees revealed no significant difference between infection groupings. 
 My findings indicate that caffeine has potential to act as an accessible and inexpensive 
method of treating viral infections, while also serving as a tool to further understanding of honey 
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CHAPTER 1: INTRODUCTION 
 
Honey bees are a keystone species in the modern crop pollination landscape, generating 
an estimated global annual value of over $215 billion USD in agricultural production (Gallai et 
al. 2009; Smith and Saunders 2016). These highly managed, charismatic insects have attracted 
global attention for their notable role in food production, as well as the apparent decline in their 
overall health. Although the global number of hives has actually risen by ~45% since 1961, this 
approximation is highly uneven across continents, with North America and Europe both 
experiencing precipitous declines in managed colony numbers while Asia, Africa, and South 
America all reported large increases (Aizen and Harder 2009; Potts et al. 2010). These declines 
cannot be attributed solely to poorer colony health, as fluctuating market demands have had 
significant impacts on overall colony numbers, but the fact that honey bees are currently 
suffering from a combination of biotic and abiotic stressors is undeniable (vanEngelsdorp and 
Mexiner 2009). Such stressors include pesticides, disease, poor forage, and the omnipresent 
Varroa mite (Varroa destructor) (vanEngelsdorp and Meixner 2009; Goulson et al. 2015), all of 
which can lead to high rates of hive loss and subsequent replacement (Steinhauer et al. 2014).  
There are also an enormous variety of pathogens capable of infecting honey bees, 
including bacteria, viruses, and microsporidia and other fungi. Viruses are of particular concern 
due to their close association with Varroa, the most widespread and devastating parasite of 
honey bees known to date (Rosenkranz et al. 2010). A large number of honey bee viruses have 
already been characterized, with the count continually rising due to the onset of next-generation 
sequencing techniques (Chen et al. 2004; McMenamin and Flenniken 2018). Although there is 
some dispute over whether or not certain species can be classified as distinct or belonging to a 
closely related overall complex, the majority of these viruses share two important qualities: (1) 
they can be vectored by Varroa mites and (2) they can cause devastating effects that range from 
poor brood survival to physiological defects and total hive collapse (Grozinger and Flenniken 
2019). One of the best known and comparatively well-studied examples is deformed wing virus 
(DWV), a virus that cripples wing functionality, reduces adult activity, and contributes to 
increased risk of overwinter hive mortality (Natsopoulou et al. 2017). Viruses belonging to the 
bee paralysis virus complex (acute bee paralysis virus, Kashmir bee virus, and Israeli acute 
paralysis virus) cause shivering wings and disorientation in workers before eventual paralysis 
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and death (Chen et al. 2014; Amiri et al. 2019; Grozinger and Flenniken 2019). Still other 
viruses, such as sacbrood virus (SBV) and black queen cell virus (BQCV), target the larval 
stages of bees, impairing hive reproduction and productivity (Allen and Ball 1996). Although 
some developing technologies used to combat virus infection have been successful to some 
extent (Maori et al. 2009; Hunter et al. 2010; Leonard et al. 2020), much of the existing virus 
work focuses on identifying novel viral species (Chen et al. 2004; McMenamin and Flenniken 
2018), with comparatively fewer studies examining their physiological impacts on honey bees. 
To date, there are currently no available treatments for any known viruses and management 
focuses mainly on reducing Varroa loads.  
The first objective of my thesis project was to test potential treatments for honey bee 
virus infections. I selected Israeli acute paralysis virus (IAPV) as a model for its simplicity of 
phenotyping and ease-of-inclusion in the experimental workflow, as well as its importance as a 
pathogen of concern. Previous virus-based physiological research has generally used DWV as a 
model due to its ubiquity among honey bees and related Apis species. However, despite the fact 
that DWV-infected larvae typically eclose with the characteristic and easily recognizable 
crumpled wing defect, adult bee infections produce much more subtle behavioral phenotypes 
(Grozinger and Flenniken 2019). In contrast, signs of acute IAPV infection (lethargic movement, 
reduced reaction to stimulus, and eventual death) are readily discernible (Chen et al. 2014). 
Using IAPV allows for high-throughput bioassays, which aim to establish an effect before 
expanding to include a wider range of applicable virus models. Following confirmation of effect 
(or lack thereof), my secondary objective was to determine whether the mechanism of effect was 
through viral tolerance, an ability to sustain increased viral loads, or viral resistance, an active 
reduction in viral replication or overall titers. 
 As with all other factors that influence honey bee health, the effects of parasites and 
pathogens must be considered in the context of the ecology and behavior of honey bees. For 
example, the diversity and quality of pollens consumed by individual bees can have a significant 
effect on their ability to tolerate pathogenic infections (Alaux et al. 2010; Dolezal et al. 2019a, 
Negri et al. 2019). Additional investigations have taken a more granular approach by examining 
individual secondary plant metabolites found in nectar, pollen, and resins that bees naturally 
ingest. These secondary metabolites, or phytochemicals, are routinely collected by foragers and 
are typically present, albeit in varying concentrations, in honey, allowing for distribution 
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throughout the hive. Many of these phytochemicals have immune-boosting effects in Apis 
species and may serve as part of a self-medication strategy among social bees (Negri et al. 2019). 
Nicotine, a phytochemical common in species of Solanaceae, can reduce the parasite load and 
infection rate of Crithidia bombi, a bumble bee gut trypanosome (Baracchi et al. 2015). In fact, 
the infected bumble bees preferentially seek out nicotine-laced solutions, despite the fact that 
nicotine typically serves as a feeding deterrent (Köhler et al. 2012), lending further support to the 
idea of self-medication (Baracchi et al. 2015). In a series of experiments, Negri et al. (2015) and 
Szawarski et al. (2019) have demonstrated that abscisic acid (ABA), a phytohormone produced 
by both floral food sources and adult honey bees themselves, plays an important role in honey 
bee immunocompetence. ABA stimulates immune response to cold stress, improves wound 
healing and pesticide tolerance, and even reduces spore loads of Nosema ceranae, a 
microsporidian parasite, at a colony level (Negri et al. 2019). However, as Negri et al. (2019) 
noted in their review, many of these phytochemicals merit further investigation with respect to 
how they affect bee physiology at an individual and colony level. More specifically, there is 
currently a dearth of studies involving the physiological effects of these phytochemicals on 
honey bee viral infections.  
I address this issue in my thesis by first screening for candidate phytochemicals with 
potential antiviral effect by using high-throughput cage experiments and then further 
investigating any phytochemicals that produce measurable benefits. Among the multitude of 
potential candidates, I selected several phytochemicals already known to have beneficial effects 
on bees, including thymol, carvacrol, p-coumaric acid (PCA), quercetin, and caffeine for viral 
treatment testing.  
 
Phytochemical Selection and Screening 
 
Essential Oils: Thymol and Carvacrol 
In recent years, there has been rising interest in the use of essential oils as both 
nutraceuticals, i.e. food components that impart physiological benefits typically to humans, and 
antimicrobial control agents in other animals (Das et al. 2012, Salehi et al. 2018). Thyme oil, 
derived from the aromatic subshrub Thymus vulgaris, and oregano oil, originating from the 
Mediterranean herb Origanum vulgare, both confer immune-boosting benefits in humans 
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including antibacterial, antifungal, antiparasitic, and antioxidative properties (Dauqan and 
Abdullah 2017; Gaur 2017; Salehi et al. 2018). The primary active components of both of these 
oils are the monoterpenes thymol and carvacrol. Independently administered, carvacrol increased 
the survivorship of bacteria-infected wax moths (Galleria mellonella) (Upadhyay and 
Venkitanarayanan 2016) and reduced cultures of Staphylococcus aureus in certain foods (Chang 
et al. 2017). Thymol, which inhibits growth of a wide variety of bacterial and fungal species and 
has been used for a broad range of traditional medicinal purposes (Salehi et al. 2018), is the 
active ingredient in the popular Varroa control treatments Apiguard® and ApiLife VAR® 
(Floris et al. 2004; Gregorc and Planinc 2005). Palmer-Young et al. (2017b) examined the effects 
of thymol (among other phytochemicals) on adult honey bees, demonstrating that short-term 
consumption of thymol resulted in reduced levels of DWV in young bees while long-term 
consumption significantly increased antimicrobial peptide expression in older bees. Palmer-
Young et al. (2017a) also observed that, as in the nicotine experiment performed by Barrachi et 
al. (2015), thymol suppresses the development of C. bombi and even interacts synergistically 
with other phytochemicals.  
 During the phytochemical screening process, I expanded upon the work performed by 
Palmer-Young et al. (2017b) by documenting the antiviral effects of thymol and carvacrol on 
Israeli acute paralysis virus (IAPV) infections in honey bee workers. Both of these essential oils 
have pungent odors in their pure form and can be difficult for humans and insects alike to ingest 
due to their topical irritant properties. In fact, thymol is naturally repellent to honey bees and 
overdosing with thymol-based mite treatments can cause them to abscond (Raffique et al. 2012; 
Colin et al. 2019). To administer what would otherwise be an intolerable dose, I first 
encapsulated thymol and carvacrol particles within ß-cyclodextrin, a cyclic oligosaccharide, 
before feeding them to honey bees inoculated with IAPV to measure how these phytochemicals 
affect survivorship. This delivery method was based on work done by Gaur (2017), who 
formulated carvacrol and thymol for administering to children by masking the overpowering 
taste of carvacrol and thymol via encapsulation using ß-cyclodextrin and then incorporating the 






p-Coumaric Acid and Quercetin 
The phenolic acid p-coumaric acid (PCA) and the flavonol quercetin both belong to the 
group of phytochemicals that are effectively ubiquitous in pollen, propolis, and honey (Mao et al. 
2009) and that provide an assortment of immune-boosting functions in honey bees. Bernklau et 
al. (2019) found that PCA improved the survivability of bees infected with N. ceranae by 
reducing the spore loads of the microsporidian parasite. Mao et al. (2013, 2015) demonstrated 
that PCA upregulates several families of cytochrome P450 genes (P450), genes responsible for 
the detoxification of xenobiotics, as well as several antimicrobial peptide genes when fed to adult 
and larval bees. Honey bees rely on these P450s to detoxify the broad range of defensive 
phytochemical compounds they encounter in their natural diet as well as pesticides and 
acaricides introduced into their hive environment (Mao et al. 2013; 2017). Liao et al. (2017) 
determined that both PCA and quercetin can extend the lifespan of bees exposed to pyrethroids 
and Wong et al. (2018) found similar survival-enhancing results when bees were fed the same 
phytochemicals in combination with imidacloprid, a neonicotinoid pesticide. It is unclear if these 
detoxification mechanisms provide protective benefits against infection.  
 Furthermore, PCA and quercetin both possess antiviral qualities, although, thus far, these 
studies have not included the use of pollinator virus models, i.e., they have been studied 
primarily in human pathogen models. Quercetin reduced the viral expression of Canine 
Distemper Virus and improved cellular viability in an in vitro mammalian cell culture assay 
(González-Búrquez et al. 2018) and PCA inhibited the replication of certain strains of human 
rhinovirus in infected human epithelial adenocarcinoma cervical cell cultures (Kwon et al. 2019). 
Human rhinovirus belongs to the order Picornavirales, to which many of the more frequently 
encountered bee viruses (DWV, IAPV, BQCV, and others) also belong (Grozinger and 
Flenniken 2019). These commonalities, in conjunction with the anti-DWV effect observed by 
Palmer-Young et al. (2017b), suggest that there may be a similar antiviral result when PCA and 
quercetin are administered to honey bees, even though previous viral studies have been 
conducted largely in mammalian cell lines. Despite some recent advances (Goblirsch et al. 203), 
there is currently no widely available honey bee continuous cell line, making the in vitro work 
like that of Kwon et al. (2019) or González-Búrquez et al. (2018) unfeasible in my 
phytochemical trials. Consequently, all of the bioassays in my study were conducted in vivo, 
examining viral effects at a physiological, rather than a cellular, level.  
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 As part of the screening process, I studied the effects of PCA and quercetin on IAPV 
infections in honey bees using the same high-throughput cage assays employed in the essential 
oil trials with the same objectives of first establishing a direction of effect before examining the 
mechanism. Based on their established immune-boosting properties, I hypothesized that both 




 Perhaps one of the most widely recognized plant secondary metabolites, caffeine is an 
alkaloid naturally found in the seeds, leaves, and berries of a wide variety of plant species 
including coffee (Coffea), cocoa (Theobroma), and tea (Camellia) (Nathanson 1984; Kretschmar 
and Baumann 1999). Apart from acting as an important stimulant for many humans, caffeine is 
capable of triggering a wide variety of behavioral and physiological reactions across a variety of 
taxa, including reducing the risk of Alzheimer’s disease in mice (Arendash et al. 2006), 
ameliorating oxidative stress in rats (Devasagayam et al. 1996), and even improving locomotory 
behavior in cockroaches (da Silva et al. 2018). Like nicotine, caffeine is toxic to many 
herbivorous insects, killing tobacco hornworm (Manduca sexta) larvae when ingested at 
naturally occurring levels, for example, indicative of its ecological function as an endogenous 
pesticide or feeding deterrent (Nathanson 1984).  
 In spite of its toxic effects, caffeine can also be found in the floral nectar and pollen of 
Coffea and citrus (Citrus) species (Kretschmar and Baumann 1999, Wright et al. 2013), where its 
defensive qualities do not appear to deter pollinator feeding. In fact, both honey bees and bumble 
bees prefer sucrose solutions containing higher concentrations of caffeine over lower 
concentrations or no caffeine at all (Singaravelan et al. 2005, Thomson et al. 2015). Si et al. 
(2005) observed that caffeine consumption increases the speed of olfactory learning in young 
bees and improves cognitive performance in complex learning tasks in older bees. Numerous 
studies have detailed the ways in which caffeine aids in the memory formation process (Mustard 
et al. 2012) with caffeine-fed bees being three times more likely to remember olfactory cues 
(Wright et al. 2013). In the field, bees stimulated by a caffeine reward intensify their recruitment 
behaviors, increasing foraging and waggle dance frequency, as well as persistence to target 
dance location (Couvillon et al. 2015). Curiously, these patterns of learning and recruitment are 
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not uniform across all pollinators; Plebeia droryana, a species of stingless bee that pollinates 
flowers in tropical habitats, have no behavioral response to caffeine ingestion (Peng et al. 2019).  
  The ecological function of secondary plant metabolites, such as caffeine, in nectar has 
long been a subject of debate. Among hypotheses advanced to account for the presence of a 
chemical that deters feeding by many herbivorous insects include reducing defense against 
robbing by non-specialists and defense against microbial contamination (Stevenson et al. 2017; 
Mustard 2020). However, Adler (2000) argues that there is no single overarching stimulus and 
the varied functions of plant secondary compounds such as caffeine are instead rooted in the fact 
that such traits are under multiple simultaneous selective pressures. For example, although 
caffeine negatively affects the herbivorous Manduca sexta larva (Nathanson 1984), it also has 
phagostimulatory effects on the pollinating adult hawk moth of the same species (Reiter et al. 
2015). Stevenson et al. (2017) suggest that secondary metabolites found in nectar act as a 
coevolutionary force between plants and pollinators but also propose that their presence may be a 
byproduct of their pleiotropic effects elsewhere within the plant. By including viral infection into 
my caffeine investigations, I hope to attain a better understanding of the evolutionary 
relationship between honey bees, caffeine, and their plant hosts. 
Despite the large body of research on behavioral effects of caffeine on honey bees, fewer 
studies have examined the physiological consequences of caffeine ingestion. Balieira et al. 
(2018) showed that caffeine helps to ameliorate the oxidative stress induced by the neonicotinoid 
insecticide imidacloprid. Both Strachecka et al. (2014) and Bernklau et al. (2019) found that 
caffeine increased the lifespan of honey bees infected by N. ceranae by actively reducing spore 
loads. However, no study has examined the effects of caffeine on viral infection, an issue that I 
addressed in this project. Using the same high-throughput cage assays, I set out to establish 
whether caffeine can improve honey bee survivorship in the presence of IAPV infection and to 
differentiate between viral tolerance versus resistance by measuring viral titers. I also generated 
caffeine dose-response curves with and without viral inoculation to provide a broader context for 




CHAPTER 2: MATERIALS AND METHODS 
 
Virus Particle Production  
Large quantities of virus particles were produced and amplified inside honey bee pupae 
using methods similar to those compiled by de Miranda et al. (2015) and Carrillo-Tripp et al. 
(2016) with minor modifications. Pupae were collected using two different methods: (1) pupal 
excision and (2) larval crawl-outs.  
For pupal excision, brood frames containing white-eye pupae were selected and removed 
from healthy hives in the University of Illinois at Urbana-Champaign (UIUC) apiary 
(Champaign County, IL). White-eye pupae were gently excised using forceps and arranged in 
groups of 8-10 in Petri dishes lined with filter paper. All excised pupae were then injected with 1 
µl of a 1% virus particle solution suspended in phosphate-buffered saline (PBS). The stock virus 
particles were provided by Dr. Adam Dolezal at UIUC and were identical to those described in 
Geffre et al. (2020). Injections were performed between the third and fourth abdominal tergites 
using a Combitip injector and a 30G needle. The Petri dishes were then stacked in a Tupperware 
container and placed in an incubator maintained at 34 ºC and 75% relative humidity for 
approximately 3 to 5 days. Daily inspections were performed and dead or rotting pupae were 
removed before bacterial or fungal buildup could occur. After allowing sufficient time for the 
virus particles to propagate, the pupae were placed into 50 ml conical tubes, homogenized by 
vortexing, and stored in the -80 ºC freezer until ready for extraction and concentration.  
Eventually, brood extractions were completed with a second method: larval crawl-outs. 
This approach results in much higher throughput with no measurable difference in viral 
production. Instead of selecting brood frames containing pupae of an approximate age, honey 
bee queens were caged on an empty frame and allowed to lay eggs for 24 hours. Following the 
egg-laying period, queens were released, and the egg frames were marked and allowed to 
develop normally within the colony. At exactly 192-hours after caging (the point right before 5th 
instar larvae are capped), marked frames were transferred to an incubator maintained at 34 ºC 
and 75% relative humidity and laid face-down (larval cells facing downwards) onto Tupperware 
containers lined with Kimwipes ®. Overnight, the food-seeking instinct of late-stage larvae 
drives them to crawl out of their cells and drop onto the padded containers below. The larvae 
were then removed from the containers and individually arranged onto shallow, plastic trays 
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lined with Kimwipes and tented with aluminum foil to retain moisture. The trays were then 
returned to the incubator and larvae were allowed to develop for an additional 5 to 6 days until 
they reached the white-eye stage, whereupon they were injected and sampled following the steps 
outlined in the pupal excision protocol.   
 
Virus Particle Extraction and Concentration 
Virus particles were grown and extracted from 8 separate colonies across 16 total 
samplings. The homogenized pupae gathered during viral production were thawed, transferred to 
centrifuge bottles, and mixed with approximately three volumes of 1X PBS on a shaker at room 
temperature for 10 minutes. The bottles were then centrifuged using a Sorvall RC-5B 
ultracentrifuge equipped with a GSA Rotor at 15,000 x g for 5 minutes at 4 ºC, after which the 
supernatant was decanted and filtered through cheesecloth to remove remaining fat globules. The 
supernatant was extracted using 0.3 volumes of 24:1 chloroform:isoamyl alcohol and centrifuged 
at 21,000 x g for 20 minutes at 4 ºC. The subsequent aqueous phase was then decanted into a 
beaker and RNAse-free water was added to bring the total volume to 200 ml. Beakers were then 
transferred to a 4 ºC cold room and placed onto magnetic stir plates. 4.6 g NaCl and 14 g 
polyethylene glycol 8000 (PEG) were slowly added to each beaker under constant gentle stirring. 
The mixtures were stirred continually for an additional 5 hours in the cold room, after which they 
were incubated overnight to allow virus particles to precipitate. Following incubation, the 
mixtures were transferred to clean bottles and centrifuged at 15,000 x g for 30 minutes at 4 ºC to 
recover a PEG-particle pellet. The pellet was then resuspended in TES buffer (10 mM Tris-HCl 
pH 7.5, 2 mM EDTA, 150 mM NaCL) and passed through an 18G needle ten times before being 
aliquoted into 2-mL centrifuge tubes. The tubes were centrifuged at 13,000 x g for 15 minutes at 
4 ºC, after which the supernatant was separated and centrifuged again at the same settings to 
ensure total removal of all PEG. The remaining supernatant was then concentrated to 
approximately 2 ml using Amicon® Ultra-4 Centrifugal Filter Unit (MilliporeSigma) via 
centrifugation at 14,000 x g for 10 minutes at room temperature. The concentrated particles were 
passed through a 26G needle and centrifuged one final time at 14,000 x g for 5 minutes at room 





Virus Particle Purification and Quantification 
RNA was extracted from the concentrated virus particles using TRIzol (Life 
Technologies) extraction and DNA was removed using DNAse I (RNase-free) (New England 
BioLabs). Based on the protocols described in Carrillo-Tripp et al. (2016), fragments of the 
IAPV genome were amplified using one-step reverse transcription (RT)-qPCR with the Power 
SYBR® Green RNA-to-CT™ 1-Step Kit (Applied Biosystems) following an absolute 
quantification approach using 100 ng total RNA per sample. Amplification was performed using 
a 384-well Quantstudio 6 Flex Real-Time PCR System (Applied Biosystems) and programmed 
as follows: reverse transcription [48 ºC – 30 min], enzyme activation [95 ºC – 10 min], PCR – 40 
cycles of [95 ºC – 15 sec, 60 ºC – 1 min], melt curve [95 ºC – 15 sec, 60 ºC – 1 min] – [stepwise 
increases of 0.05 ºC/sec from 60-95 ºC, hold for 15 min]. The final copy numbers are 
extrapolated using a 1:10 serially diluted RNA-based standard curve containing sequences of the 
viruses of interest (Carrillo-Tripp et al. 2016).   
 
Cage Assays: General Protocol 
The following protocol describes the universal processes shared by all subsequent cage 
assays. Specific details regarding experimental treatments, treatment concentrations, sample size, 
and testing duration can be found in their corresponding subsections. 
Five+ frames of bees on the verge of eclosion (<24 hours) sourced from at least three 
separate hives located within the University of Illinois at Urbana Champaign (UIUC) apiary 
were placed into emergence boxes and stored inside a 34 ºC incubator set to 50% relative 
humidity. After 24 hours, all frames were removed and newly emerged bees were brushed into a 
single collection tub. In order to minimize the hive genetic effects of any individual colony, all 
bees were gently mixed to produce a homogeneous mixture before being separated into acrylic 
cages with 35 bees per cage. The cages were then transferred to the same incubator and 
randomly arranged to prevent any microclimate effects. Immediately following the transfer, each 
cage received a small weigh boat containing either 600 µl of 30% sucrose solution mixed with an 
IAPV inoculum or an equivalent quantity of sterile but otherwise untreated sucrose solutions (see 
associated subsections for concentrations of viral inocula employed in particular experiments). 
After allowing for total consumption of inocula within all cages (approximately 12-14 hours), 
feeder tubes (15 mL Falcon tubes with 18G needle holes poked in the bottom) were inserted into 
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each cage, the contents of which were provided ad libitum and refilled as necessary throughout 
the course of each experiment (see subsections for experiment-specific feeder solutions). 
Mortality within every cage was recorded at 12-hour intervals for the first 72 hours of each 
experiment, following which recordings were switched to 24-hour intervals. Dead bees were 
removed following each instance of mortality observation to avoid repeated count errors. 
Although bees were not sampled from every experiment, every experiment in which bees were 
sampled followed an identical protocol: three bees were haphazardly selected at 36-hours post-
inoculation (hpi) and placed into centrifuge tubes on dry ice. Dead bees were given priority over 
live bees for sampling to minimize depopulating the cages. The 36-hpi timepoint was selected as 
past experimentation has shown that this tends to be the point at which IAPV titers are highest 
within the bee without inducing lethal effects (Dolezal et al. 2019).  
 
IAPV Yearly Dose Establishment 
1. Virus Dose-Response (2018, 2019) 
In order to ascertain which viral concentration would result in approximately 65% in-
cage survival at 36-hpi (sufficient for detecting differences between treatments without inducing 
total-cage mortality too rapidly), IAPV dose-response curves were generated in both field 
seasons (summers of 2018 and 2019) prior to phytochemical experimentation.  
 
2018: The cages were split into six viral treatments and one control, resulting in 7 cages per 
treatment, for a total of 49 cages. The inocula used in viral treatments were generated using 1:10 






 stock IAPV particles in 30% sucrose solution 
(denoted as 10-2 to 10-7). Control treatments received an equivalent amount of unamended 30% 
sucrose solution. Following inocula ingestion, all cages received feeder tubes containing 30% 
sucrose solution and were monitored for 7 days. This dose-response trial was subsequently 
repeated using identical experimental parameters with the exception of excluding treatments 10-5, 
10-6, and 10-7 due to their virtually indistinguishable results. No sampling was performed for 




2019: Novel dose-response curves were generated for the second field season instead of relying 
on previously established dosages in case of potential particle degradation. These trials followed 
identical protocols to the 2018 series with a few minor changes: only concentrations 10-2, 10-3, 
10-4, and a control were tested (n = 21, 21, 14, and 21, respectively) and the cages were 
monitored for 4 days instead of 7.  
 
Table 1. Summary of the virus dose-response experiment parameters. Concentrations represent 
1
100
  to 
1
10,000,000
 IAPV particles in 30% sucrose solution (denoted as 10-2 to 10-7); C = unamended 
sucrose control. Cages indicate number of cages per concentration per trial; final row in each 
year lists cages per concentration in order of concentration. 
 
Year Trial # Concentrations Cages  Duration (days) 
2018 
1 C, 10-2, 10-3, 10-4, 
10-5, 10-6, 10-7 
7 7 





C, 10-2, 10-3, 10-4, 
10-5, 10-6, 10-7 
14, 14, 14, 14, 
7, 7, 7 
- 
2019 
1 C, 10-2, 10-3 7 4 
2 C, 10-2, 10-3, 10-4 7 4 
3 C, 10-2, 10-3, 10-4 7 4 
 Total per 
concentration 
C, 10-2, 10-3, 10-4 21, 21, 21, 14 - 
 
I. Phytochemical Screening 
2. Carvacrol Dose-Response 
To decide on an experimental carvacrol dose, I tested concentrations scaled around a 
previously tested concentration of thymol, an isomer of carvacrol (Palmer-Young et al. 2017b). 
This preliminary testing followed a simplified version of the standard cage protocol, which did 
not include a viral inoculation phase or bee sampling but instead provided cages with ad libitum 
carvacrol solution for the entire duration of the trial. Six carvacrol concentrations (160, 16, 1.6, 
0.16, and 0.016 ppm) and a control were tested for 14 days; n = 5 cages per treatment (n = 30 
cages total). All carvacrol solutions used in this and subsequent experiments were produced by 
mixing 30% sucrose solution with encapsulated carvacrol particles provided by Dr. Juan 




3. Carvacrol Moderate Dose Treatment 
Based on the carvacrol dose response curve generated in Experiment 2, I tested whether a 
160 ppm carvacrol solution affects IAPV infection using the standard cage assay protocol. The 
experiment consisted of four treatments (10-2 IAPV inoculated and uninoculated controls, 10-2 
IAPV inoculated and uninoculated 160 ppm carvacrol), ran for 7 days (168-hpi), with 7 cages 
per treatment, and no sampling was performed. Note that this experiment ran concurrently with 
Trial 2 of 2018 from Experiment 1 due to field season time constraints. 
4. Carvacrol Acute Rescue  
Following the standard cage assay protocol, virally inoculated bees were fed elevated 
levels of carvacrol to determine whether the essential oil could act as therapeutic agent for cases 
of acute IAPV infection. The experiment consisted of an uninoculated control, two carvacrol 
concentrations (1,000 and 2,000 ppm) that were either inoculated or uninoculated with 10-2 
IAPV, ran for 3 days (72-hpi), with 7 cages per treatment (35 cages total), and no sampling was 
performed (Table 2).  
 
Table 2. Summary of carvacrol acute rescue experiment details. IAPV column denotes presence 
(+) or absence (-) of a 0.01% IAPV inoculum.  
 
Diet Type Concentration IAPV (10-2) 
Control (30% sucrose)  N/A - 
Carvacrol 
1,000 ppm - + 
2,000 ppm - + 
 
5. Thymol Acute Rescue, Prophylactic, and Regular Treatment 
The effects of thymol supplementation were tested across three treatment forms: acute 
rescue response, ad libitum feeding, and prophylactic treatment. Both acute rescue (1,000 ppm 
thymol) and ad libitum (160 ppm thymol) feeding treatments with or without 10-2 IAPV 
inoculation followed the standard cage assay protocol, running for 11 days (264-hpi), with 7 
cages per treatment, and no sampling being performed (Table 3). The prophylactic treatments 
were tested using the same parameters but differed in their virus inoculation schedules. Instead 
of being fed a virus inoculum immediately after being separated into cages, bees in the 
prophylactic treatments received 160 ppm thymol-sucrose solution ad libitum (with controls 
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instead receiving 30% sucrose) for 6 days before being fed the standard virus inoculum. 
Following inoculation, both treatments were switched to a sucrose-only diet and monitoring was 
performed as normal. 
 
Table 3. Summary of thymol acute rescue experiment details. IAPV column denotes presence 
(+) or absence (-) of a 0.01% IAPV inoculum. 
 
Treatment Thymol concentration IAPV (10-2) 
Control – standard 0 ppm  - 
Ad libitum 160 ppm - + 
Acute Response 1,000 ppm - + 
Prophylactic – Control 0 ppm; 0 ppm + 
Prophylactic – Inoculated 160 ppm; 0 ppm + 
 
II. Caffeine Investigation 
6. Differentiating Caffeine in Multiple Phytochemical Trial 
Following the standard cage assay protocol, virus inoculated bees were subjected to three 
different phytochemical treatments with or without 10-4 IAPV inoculation: p-coumaric acid (82 
ppm), quercetin (75.6 ppm), and caffeine (25 ppm). All feeder solutions contained 0.25% DMSO 
in order to solubilize p-coumaric acid (PCA) and quercetin (Liao et al. 2017). Concentrations for 
PCA and quercetin were selected based on the natural range observed in local honey and 
beebread (Liao et al. 2017) and 25 ppm caffeine was selected based on the natural range in which 
the substance is found in Citrus and Coffea nectar (11.7 – 95 ppm) (Kretschmar and Baumann 
1999; Wright et al. 2013). The experiment ran for five days (120-hpi), with 10 cages per 
treatment (80 cages total), and standard sampling was performed (see Table 4 for treatment 
details). All treatments were evenly divided into two concurrent trials initiated within 24 hours of 
one another for practical reasons. 
 
Table 4. Summary of multi-phytochemical experiment details. IAPV column denotes presence 
(+) or absence (-) of a 0.0001% IAPV inoculum. 
 
Treatment Concentration IAPV (10-4) 
Control N/A - + 
Quercetin 75.6 ppm - + 
p-Coumaric Acid 82 ppm - + 




7. Caffeine Trial  
Focusing on the effects of caffeine on viral infection, a subcomponent of Experiment 6 
was replicated by repeating only the control and caffeine treatments (Table 4). The sample sizes 
were increased to 20 cages per treatment (80 cages total), but all other experimental parameters 
were held constant. Treatments were split into two concurrent trials (see Experiment 6). 
8. Caffeine Dose Responses (8A, 8B) 
To determine honey bee reactions to a range of caffeine concentrations, two separate 
caffeine dose response curves were generated: one testing IAPV inoculated bees and the other 
testing un inoculated bees. The uninoculated dose response trial (Experiment 8A) followed the 
standard cage assay protocol and four caffeine concentrations (25, 100, 1000, and 10,000 ppm) 
and a control (30% sucrose), all of which were inoculated with 10-4 IAPV, were tested. The test 
ran for 7 days (168-hpi), with 20 cages per treatment (100 cages total), and standard sampling 
was performed. The uninoculated dose response trial (Experiment 8B) followed an identical 
protocol to Experiment 8A with the following two exceptions: (1) all cages received a virus-free 
inoculum containing only sucrose solution and (2) testing ran for 12 days (288-hpi). Caffeine is 
sufficiently soluble in sucrose solution so DMSO was not used in any of the treatments, as in 
Experiments 6-7. Both Experiments 8A and 8B were split into two concurrent trials (see 
Experiment 6).  
 
Sampled Bee Homogenization for Viral Quantification  
To confirm infection and address the question of viral tolerance vs. resistance, I 
quantified the viral titers of the caffeine-fed bees and their control counterparts sampled from 
Experiments 6 and 7. I purposefully selected only dead bees from all treatments for 
quantification to guarantee the selection of a known IAPV phenotype (i.e., death). In order to 
homogenize the sampled bees across all collected treatments, 8 cages were randomly selected 
with the use of a random number generator from each of the four treatments (caffeine+, - and 
control+, -) pooled across Experiments 6 and 7; for a total of 32 cages. From each cage, 2 out of 
the 3 sampled bees were selected for quantification; n = 64 samples. Dead bees were ‘simulated’ 
in the treatments with fewer than necessary dead-upon-collection samples (i.e. the uninoculated 
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cages) by haphazardly selecting bees sourced from uninoculated treatments previously killed via 
freezing at -80 ºC, placing them into empty cages, and transferring them to an incubator (34 ºC, 
50% RH). After 12 hours of incubation, the simulated dead bees were removed from their cages 
and immediately processed for viral quantification using the previously stated methodology.  
 
Statistical Analyses 
Survival analyses in Experiments 2-5 were conducted using Cox Proportional Hazard 
modeling performed in R using the survival (version 3.1-11) and survminer (version 0.4.6) 
packages. Experiments 6-8 were subdivided into two concurrent trials each that were initiated 
within 24 hours of one other. Consequently, these experiments were analyzed using mixed 
effects Cox models in the coxme package (version 2.2-16) to account for the trial factor. 
Subsequent pairwise comparisons within all Cox models were corrected using Benjamini-
Hochberg corrections to reduce Type I error rate. Viral loads obtained from RT-qPCR were 
estimated using QuantStudio RealTime PCR Software (Applied Biosystems, version 1.3) and 
then analyzed with R using the dplyr package (version 0.8.3). Normality assumptions were not 
met despite Box-Cox transformations, and thus the data were analyzed using the Kruskal-Wallis 
rank sum test. Pairwise differences were determined using Wilcoxon rank sum and multiple 
comparisons were corrected using Benjamini-Hochberg corrections. All graphics were generated 





CHAPTER 3: RESULTS 
 
IAPV Yearly Dose Establishment 
 
All experiments involving viral infection used the same purified 99.9% IAPV particles 
produced in the summer of 2018 using the previously described virus isolation methods.   
In 2018, the 1% virus solution (10-2) was selected as the target concentration for all cage 
experiments conducted that year (Experiments 2-5) based on the 36-hpi survival rate (Figure 
1A). In 2019, all tested treatments (10-2 – 10-4) experienced a rise in mortality compared to 2018 
(Figure 1B). As a result, the 0.01% virus solution (10-4) was selected as the target concentration 
for all subsequent cage experiments (Experiments 6-8). 
  
Figure 1.  Dose-response survival curves of honey bee cages inoculated with IAPV in 2018 (A) 
and 2019 (B) at 0 hours post-infection. Treatments represent IAPV inocula concentrations with 






 stock IAPV particles in 30% sucrose solution; controls were 








I. Phytochemical Screening (Experiments 2-6) 
 
Carvacrol Screening 
In the carvacrol dose-response experiment, responses of bees in control cages fed 
unamended sucrose did not differ significantly from responses of bees in cages fed the lower 
concentrations of carvacrol tested (0.016, 0.16 ppm) (Figure 2). When compared to the control, 
consuming 16 or 160 ppm carvacrol significantly increased mortality risk by 37.9% and 62%, 
respectively, but neither of the two treatments were significantly different from one another 
(Table 5). As a result, the higher of the two concentrations, 160 ppm, was selected for additional 
screening to maximize the chances of discerning an effect. 
 
Figure 2. Dose-response survival curves of honey bee cages fed varying concentrations of 
carvacrol in 30% sucrose solution, line colors indicative of treatment. n = 5 cages per 
concentration. NS, not significant (pairwise Cox proportionate hazards models, Benjamini-









Table 5. Hazard ratios (HR) of pairwise Cox proportionate hazards model comparisons between 
treatments in the carvacrol dose-response trial (Exp. 2). Blue and red HRs indicate significant 
increased and decreased risk of death, respectively (*p < 0.05, **p < 0.01, ***p < 0.001; 
Benjamini-Hochberg correction). Comparisons are read from left-row to top-column; e.g. Row 2 
treatment increases or decreases risk of death by a factor of x when compared to Column 3. 
Control = sucrose only. n = 5 cages for all treatments. 
 
 0.016 ppm 0.16 ppm 1.6 ppm 16 ppm 160 ppm 
0.016 ppm N/A N/A N/A N/A N/A 
0.16 ppm 0.681 N/A N/A N/A N/A 
1.6 ppm 1.250* 2.234*** N/A N/A N/A 
16 ppm 1.262** 1.715*** 1.327 N/A N/A 
160 ppm 1.201*** 1.441*** 1.181* 1.042 N/A 
Control 0.950 1.030 0.785*** 0.621*** 0.380*** 
 
Overall, none of the tested carvacrol treatments improved the survivorship of IAPV- 
inoculated bees relative to their control treatments. Neither the inoculated (HR = 1.01, p = 0.964) 
nor uninoculated (HR = 0.61, p = 0.319) 160 ppm carvacrol treatments significantly altered 
survival compared to controls (Figure 3, Table 6). Note that the inoculated control data set 
included in Experiment 3 are from the 2018 virus dose-response trials (Figure 1A) to provide a 
frame of reference, but these data were not produced concurrently with the remaining three 
treatments and are thus not present in the analysis. The higher concentrations used in the acute 
rescue trial (1,000 ppm, 2,000 ppm) not only failed to improve survivorship, they increased the 
mortality rate (Figure 4). Surprisingly, the bees in the inoculated 1,000 ppm treatment had a 
significantly higher hazard risk than those in the inoculated 2,000 ppm treatment (HR = 0.90, p < 
0.001), but the survivorship of the bees in the uninoculated 1,000 ppm treatment was not 
significantly from that of the control bees (HR = 1.68, p = 0.22) while the survivorship of bees in 





Figure 3. Average survival curves of honey bee cages inoculated (+) or uninoculated (-) with 
IAPV and fed diets of 30% sucrose solution or 160 ppm carvacrol-sucrose solution. Note this 
Figure contains inoculated control data from a separate assay run under identical experimental 
conditions as a point of reference.  n = 7 cages per treatment. NS, not significant (pairwise Cox 
proportionate hazards models, Benjamini-Hochberg correction). 
 
Table 6. Hazard ratios (HR) of pairwise Cox proportionate hazards model comparisons between 
treatments in the carvacrol treatment trial (Exp. 3). Blue and red HRs indicate significant 
increased and decreased risk of death, respectively (***p < 0.001; Benjamini-Hochberg 
correction). Comparisons are read from left-row to top-column; e.g. Row 2 treatment increases 
or decreases risk of death by a factor of x when compared to Column 3. + (IAPV inoculated), - 
(uninoculated); Control = sucrose only, CV = 160 ppm carvacrol. n = 7 cages for all treatments. 
 
 Control- CV- CV+ 
Control- N/A N/A N/A 
CV- 0.606 N/A N/A 
CV+ 4.199*** 28.465*** N/A 






Figure 4. Average survival curves of honey bee cages inoculated (+) or uninoculated (-) with 
IAPV and fed diets of 30% sucrose solution or high concentration carvacrol-sucrose solution. No 
difference was detected between survival of all uninoculated treatments except for 2000-, which 
experienced significantly lower survival than all other uninoculated treatments. n = 7 cages per 
concentration. NS, not significant; **p < 0.01, ***p < 0.001 (pairwise Cox proportionate hazards 
models, Benjamini-Hochberg correction). 
 
Table 7. Hazard ratios (HR) of pairwise Cox proportionate hazards model comparisons between 
treatments in the carvacrol acute rescue trial (Exp. 4). Blue and red HRs indicate significant 
increased and decreased risk of death, respectively (**p < 0.01, ***p < 0.001; Benjamini-
Hochberg correction). Comparisons are read from left-row to top-column; e.g. Row 2 treatment 
increases or decreases risk of death by a factor of x when compared to Column 3. + (IAPV 
inoculated), - (uninoculated); Control = sucrose only. n = 7 cages for all treatments.  
 
 Control 1000 ppm- 1000 ppm+ 2000 ppm- 
Control N/A N/A N/A N/A 
1000 ppm- 1.677 N/A N/A N/A 
1000 ppm+ 7.559*** 34.276*** N/A N/A 
2000 ppm- 2.029*** 2.215*** 0.111*** N/A 





 None of the three thymol dosing strategies proved to be effective in improving 
survivorship of IAPV-inoculated bees. Although there was no significant difference detected 
between the uninoculated 160 ppm thymol treatment and the control, hazard modeling showed a 
very strong trend toward improved relative survivorship in the thymol-fed cages (HR = 0.66, p = 
0.065).  By contrast, the mortality in the inoculated 160 ppm thymol treatment was much higher 
when compared to the carvacrol treatment at the same dose (Figure 3, 5). Furthermore, the 
inoculated 1,000 ppm thymol experienced significantly lower survivorship than the uninoculated 
1,000 ppm (HR = 2.69, p < 0.001), with bees in both treatments experiencing sharp declines in 
survivorship (~5% survival at Day 11), although this drop did not begin in the uninoculated 
group until Day 5 (Figure 5). Additionally, thymol does not appear to provide any prophylactic 
protective effect. After viral inoculation on Day 5, survival rates of bees in both prophylactic 
treatments rapidly dropped and the trial concluded with no significant difference between the 
two treatments (HR = 1.16, p = 0.168).  
 
Figure 5. Average survival curves of honey bee cages inoculated (+) or uninoculated (-) with 
IAPV and fed varying concentrations of thymol-sucrose solution. “Pro” denotes prophylactic 
treatments in which inoculation did not occur until day 5.  No difference was detected between 
the prophylactic treatments. n = 7 cages per treatment. NS, not significant; ***p < 0.001 
(pairwise Cox proportionate hazards models, Benjamini-Hochberg correction). 
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Table 8. Hazard ratios (HR) of pairwise Cox proportionate hazards model comparisons between 
treatments in the thymol trial (Exp. 5). Blue and red HRs indicate significant increased and 
decreased risk of death, respectively (**p < 0.01, ***p < 0.001; Benjamini-Hochberg 
correction). Comparisons are read from left-row to top-column; e.g. Row 2 treatment increases 
or decreases risk of death by a factor of x when compared to Column 3. + (IAPV inoculated), - 
(uninoculated); Control = sucrose only, ProCon = prophylactic fed sucrose only, ProTY = 
prophylactic fed thymol then sucrose; n = 7 cages for all other treatments.  
 
 Control 160 ppm- 160 ppm+ 1000 ppm- 1000 ppm+ ProCon+ 
Control N/A N/A N/A N/A N/A N/A 
160 ppm- 0.658 N/A N/A N/A N/A N/A 
160 ppm+ 2.923*** 12.697*** N/A N/A N/A N/A 
1000 ppm- 2.078*** 3.770*** 0.595*** N/A N/A N/A 
1000 ppm+ 1.951*** 2.810*** 1.148** 2.690*** N/A N/A 
ProCon+ 1.433*** 1.773*** 0.790*** 0.812*** 0.296*** N/A 
ProTY+ 1.372*** 1.615*** 0.842*** 0.910** 0.560*** 1.157 
 
Multi-phytochemical Screening 
 All of the treatments involving uninoculated bees in the multi-phytochemical trial were 
not significantly different from one another, with the exception of uninoculated bees consuming 
quercetin, which survived significantly better than uninoculated bees consuming caffeine (HR = 
0.46, p < 0.001) (Figure 6). However, in the inoculated group, only mortality risk for caffeine-
fed bees differed significantly from mortality risk in all other treatments, with their mortality risk 
reduced by 21.9% when compared to the inoculated control (HR = 0.78, p = 0.008) (Table 9). As 




Figure 6. Average survival curves of honey bee cages inoculated (+) or uninoculated (-) with 
IAPV and fed sucrose solution (control), caffeine (caff), p-coumaric acid (PCA), or quercetin 
(quer). Caffeine- experienced significantly lower survival than quercetin-; all other (-) treatments 
were not significantly different from one another. Caffeine+ experienced significantly higher 
survival than all other (+) treatments; all other (+) treatments were not significantly different 
from one another. n = 10 cages per treatment. NS, not significant; *p < 0.05, **p < 0.01 
(pairwise Cox proportionate hazards models, Benjamini-Hochberg correction). 
 
Table 9. Hazard ratios (HR) of pairwise Cox mixed effects model comparisons between 
treatments in the multi-phytochemical trial (Exp. 6). Blue and red HRs indicate significant 
increased and decreased risk of death, respectively (*p < 0.05, **p < 0.01, ***p < 0.001; 
Benjamini-Hochberg correction). Comparisons are read from left-row to top-column; e.g. Row 2 
treatment increases or decreases risk of death by a factor of x when compared to Column 3. + 
(IAPV inoculated), - (uninoculated); Control = sucrose only, Caff = caffeine, PCA = p-coumaric 
acid, Quer = quercetin. n = 9 cages for Caff+; n = 10 cages for all other treatments.  
 
 Control- Control+ Caff- Caff+ PCA- PCA+ Quer- 
Control- N/A N/A N/A N/A N/A N/A N/A 
Control+ 6.416*** N/A N/A N/A N/A N/A N/A 
Caff- 1.101 0.185*** N/A N/A N/A N/A N/A 
Caff+ 1.561*** 0.781** 3.254*** N/A N/A N/A N/A 
PCA- 1.034 0.547*** 0.920 0.228*** N/A N/A N/A 
PCA+ 1.440*** 0.948 1.743*** 1.245*** 7.223*** N/A N/A 
Quer- 0.870 0.585*** 0.755* 0.460*** 0.637 0.058*** N/A 
Quer+ 1.297*** 0.971 1.390*** 1.112*** 1.882*** 0.978 15.884*** 
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II. Caffeine Investigation 
 
Caffeine Trials 
The survival trends of the second set of caffeine trials (Exp. 7) remained consistent with 
those of the multi-phytochemical trial (Figure 6). Combining the results of both trials (Figure 7) 
does not significantly alter the magnitude of effect (HR = 0.86, p = 0.005), with the hazard ratios 
between inoculated caffeine and inoculated control treatments of both trials remaining within 
95% confidence intervals of one another. 
 
Figure 7. Average survival curves of honey bee cages inoculated (+) or uninoculated (-) with 
IAPV and fed sucrose solution or 25 ppm caffeine. Note this Figure contains control and caffeine 
data collected from a separate assay run under identical experimental conditions. No difference 
was detected between uninoculated treatments while caffeine+ experienced significantly higher 
survival than control+. n = 30 cages per treatment. NS, not significant; **p < 0.01 (pairwise Cox 







Table 10. Hazard ratios (HR) of pairwise Cox mixed effects model comparisons between 
treatments in the caffeine only trials (Exp. 7 + part of Exp. 6). Note this table contains the control 
and caffeine data from Table B. Blue and red HRs indicate significant increased and decreased 
risk of death, respectively (**p < 0.01, ***p < 0.001; Benjamini-Hochberg correction). 
Comparisons are read from left-row to top-column; e.g. Row 2 treatment increases or decreases 
risk of death by a factor of x when compared to Column 3. + (IAPV inoculated), - 
(uninoculated); Control = sucrose only, Caff = 25 ppm caffeine. n = 29 cages for Caff+, 30 cages 
for all other treatments.  
 
 Control- Control+ Caff- 
Control- N/A N/A N/A 
Control+ 6.423*** N/A N/A 
Caff- 1.117 0.200*** N/A 
Caff+ 1.690*** 0.863** 3.554*** 
 
Caffeine Dose-Response 
 In the caffeine dose-response trial with inoculated bees (Exp. 8A), 100 ppm caffeine 
significantly decreased mortality risk by 13.5% and 34.3% when compared to the inoculated 
control and 25 ppm caffeine, respectively (HR = 0.87, p = 0.002; HR = 0.66, p < 0.001) (Table 
11). The control and 25 ppm treatment were not significantly different from one another but 
there was a trend for bees in the 25 ppm treatment to experience an increased mortality risk (HR 
= 1.61, p = 0.083), a result directly in contrast to the results observed in previous caffeine trials 
(Figures 7, 8). Both of the elevated dosages (1,000 ppm and 10,000 ppm) significantly increased 
mortality risk when compared to all other treatments, with all cages with 10,000 ppm caffeine 




Figure 8A. Average survival curves of honey bee cages inoculated with IAPV and fed varying 
concentrations of caffeine-sucrose solution (10k = 10,000 ppm). No difference was detected 
between control and 25 ppm; 100 ppm experienced significantly higher survival than both 
control and 25 ppm (**p < 0.01, *** p < 0.001, respectively). n = 20 cages per treatment. NS, 
not significant; pairwise Cox proportionate hazards models, Benjamini-Hochberg correction. 
 
Table 11. Hazard ratios (HR) of pairwise Cox mixed effects model comparisons between 
treatments in the inoculated caffeine dose-response trial (Exp. 8). Blue and red HRs indicate 
significant increased and decreased risk of death, respectively (**p < 0.01, ***p < 0.001; 
Benjamini-Hochberg correction). Comparisons are read from left-row to top-column; e.g. Row 2 
treatment increases or decreases risk of death by a factor of x when compared to Column 3. 
Control = sucrose only. n = 20 cages per treatment. 
 
 Control 25 ppm 100 ppm 1000 ppm 
Control N/A N/A N/A N/A 
25 ppm 1.612 N/A N/A N/A 
100 ppm 0.865** 0.657*** N/A N/A 
1000 ppm 1.133*** 1.111** 1.892*** N/A 
10k ppm 1.639*** 1.771*** 3.175*** 4.722*** 
 
 In the caffeine dose-response trial with uninoculated bees (Exp. 8B), the 25 ppm dose 
significantly decreased mortality risk by 21.6% when compared to the uninoculated control (HR 
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= 0.78, p = 0.012) (Figure 9). This differentiation between the control and 25 ppm was not 
observed in the caffeine trials (Exp. 6, 7) between the same treatments tested under the same 
conditions. The remaining treatments each increased the mortality risk in the order of 10,000 
ppm > 1,000 ppm > 100 ppm > control, with 10,000 ppm dropping to near complete mortality in 
all cages by Day 3 (Table 12). 
 
  
Figure 8B. Average survival curves of honey bee cages fed varying concentrations of caffeine-
sucrose solution (10k = 10,000 ppm). 25 ppm experienced significantly higher survival than all 
other treatments; control experienced significantly higher survival than all treatments but 25 












Table 12. Hazard ratios (HR) of pairwise Cox mixed effects model comparisons between 
treatments in the uninoculated caffeine dose-response trial (Exp. 8). Blue and red HRs indicate 
significant increased and decreased risk of death, respectively (*p < 0.05, **p < 0.01, ***p < 
0.001; Benjamini-Hochberg correction). Comparisons are read from left-row to top-column; e.g. 
Row 2 treatment increases or decreases risk of death by a factor of x when compared to Column 
3. Control = sucrose only. n = 20 cages per treatment. 
 
 Control 25 ppm 100 ppm 1000 ppm 
Control N/A N/A N/A N/A 
25 ppm 0.784* N/A N/A N/A 
100 ppm 1.105** 1.516*** N/A N/A 
1000 ppm 1.323*** 1.686*** 1.894*** N/A 
10k ppm 1.947*** 2.494*** 3.346*** 8.125*** 
 
Caffeine Cages Viral Quantification 
RT-qPCR confirmed the presence of IAPV infection in the inoculated treatments (Figure 
9). The bees sampled from both inoculated treatments contained significantly higher viral loads 
than the uninoculated bees of either diet type (caffeine p = 0.019; control p = 0.004). However, 
no significant differences in viral loads were detected within the infection groups across the diet 
treatments (inoculated p = 0.645; uninoculated p = 0.641) (Kruskal-Wallis ANOVA, χ2 = 17.03, 
df = 3, p < 0.001; Wilcoxon rank-sum post-hoc; Benjamini-Hochberg corrections). Three cages 
were discarded from final analysis due to contamination, resulting in total n = 29 cages (caffeine- 




Figure 9. IAPV loads (log estimated genome equivalents per 100 ng total RNA) of bees sampled 
from the caffeine survival trials (Exp. 6-7) using RT-qPCR. Bars represent averages of pooled 
samples of inoculated (+) and uninoculated (-) treatments across both diet types (± 1 standard 
error). Letters denote significant differences between groups, Kruskal-Wallis ANOVA, 
Wilcoxon rank-sum post-hoc test, Benjamini-Hochberg correction, p < 0.05. n = 8 for both 
inoculated treatments, n = 6 and 7 for caffeine- and control- treatments, respectively.  
 
Table 13. Reference table describing all experiments and their associated figures and statistics. 
 
Experiment Description Figure Table(s) 
Exp. 1 Virus dose-response trial from 2018, 2019 Fig. 1 Table 1 
Exp. 2 Carvacrol dose-response trial (0.016 – 160 ppm) Fig. 2 Table 5 
Exp. 3 Carvacrol moderate dose treatments Fig. 3 Table 6 
Exp. 4 Carvacrol acute dose treatments (1,000 – 2,000 ppm) Fig. 4 Tables 2, 7 
Exp. 5 Thymol treatments (acute dose, prophylactic, 160 ppm) Fig. 5 Tables 3, 8 
Exp. 6 Multi-phytochemical trial (quercetin, PCA, caffeine) Fig. 6 Tables 4, 9 
Exp. 7 All caffeine 25 ppm treatments  Fig. 7 Table 10 
Exp. 8A Inoculated caffeine dose-response trial Fig. 8A Table 11 
Exp. 8B Uninoculated caffeine dose-response trial Fig. 8B Table 12 





CHAPTER 4: DISCUSSION 
 
Phytochemical Screening 
Overall, phytochemical screening process determined that neither of the two tested 
essential oils in their encapsulated forms is capable of ameliorating the effects of IAPV infection. 
These results were reflected in all tests for both phytochemicals, regardless of concentration 
(Figures 3-5). Although carvacrol has been shown to have antibacterial properties (Upadhyay 
and Venkitanarayanan 2016, Chang et al. 2017), there has been little to no examination of 
carvacrol as an agent for pathogen treatment in honey bees. My results suggest that, at least in its 
encapsulated form, carvacrol does not possess antiviral properties. Thymol, on the other hand, 
has been shown to be an effective antipathogenic agent in Apis species, upregulate antimicrobial 
peptide expression in honey bees, and able to suppress Crithidia bombi in bumble bees (Palmer-
Young et al. 2017a, b). The acaricidal properties of thymol are well-documented and their use for 
Varroa mite control has risen in popularity with formulations such as Apiguard® or ApiLife 
VAR® (Floris et al. 2004; Gregorc and Planinc 2005). The 160-ppm dose implemented in the 
thymol treatments trial (Exp. 5) falls within the range of thymol residue concentrations that can 
be found in hive wax after a standard two-week Apiguard® treatment (147.7 ± 188.9 ppm) 
(Floris et al. 2004). Despite this value being two orders of magnitude greater than the thymol 
concentration detected in honey in the same experiment (0.96 ± 0.61 ppm), a previous study has 
shown that honey bees can consume a similar thymol dose without negative effects. Indeed, 
Costa et al. (2009) showed that bees fed 100 ppm thymol syrup not only survived significantly 
longer than control bees, they also had significantly reduced Nosema ceranae spore loads. 
Although it is possible the uninoculated 160-ppm thymol treatment could have yielded a similar 
longevity-boosting result had the thymol treatment experiment been extended past 11 days (a 
non-significant trend is visible in Figure 5 between 160 ppm- and control), neither the 160- nor 
the 1,000-ppm concentration is capable of improving survival in the presence of IAPV infection 
(Figure 5). Furthermore, thymol does not appear to prevent viral infection, as suggested by the 
two prophylactic treatments. Bees in both treatments experienced decreases in survivorship at 
similar rates following inoculation on Day 5, but additional testing will be needed to fully assess 
any potential prophylactic qualities.  
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One possibility for future testing would be to reduce the amount of time during which 
both essential oils are consumed. The young bees observed to experience DWV-level reduction 
by Palmer-Young et al. (2017b) were fed thymol solution for only 24 hours before being released 
into a hive—suggesting that the antiviral qualities of thymol are effective only in the short term. 
Additionally, subsequent tests involving encapsulated essential oils should confirm whether or 
not the phytochemical was taken up by the honey bee itself. One major advantage of 
encapsulating essential oils is that the oligosaccharide coating masks the powerful odor of the 
phytochemical in its pure form, allowing for the administration of much higher doses than would 
otherwise be repellent to honey bees (Colin et al. 2019). Although the coating surrounding the 
particles is easily broken down within a human digestive system (Gaur 2017), it is possible that 
the honey bee digestive tract might not be as adept at releasing encapsulated phytochemicals, 
and, thus, the bees may not be actually gaining any therapeutic benefits. According to Ellis and 
Baxendale (1997), thymol is about 10 times more toxic to honey bees than carvacrol, yet the 
uninoculated bees in the160- and 1,000-ppm carvacrol treatments had roughly the same survival 
rate as the equivalent thymol treatments at the same time points (Figures 3-5). However, the 
carvacrol and thymol treatments were never run concurrently with one another, so these 
similarities are based entirely on survival trends rather than an established lack of 
oligosaccharide release. In fact, the rapid decline of the uninoculated bees in the 1,000 ppm 
thymol-fed cages relative to the bees in the uninoculated control cages in Experiment 5 suggests 
that thymol was being released and subsequently overdosing the bees (Figure 5). Additionally, 
Ellis and Baxendale’s (1997) assay was performed using phytochemical fumigants instead of 
direct ingestion, meaning that the magnitude of toxicity may not be directly translatable to the 
system I tested. Further investigations will be needed to validate the results obtained in my 
experiments on encapsulated carvacrol and thymol and IAPV infection. 
 The screening process also revealed that neither p-coumaric acid nor quercetin were 
capable of improving the survivorship of honey bees inoculated with IAPV (Figure 6). Both of 
these phytochemicals possess multiple survivorship-boosting capabilities, including reducing N. 
ceranae spore load, upregulating detoxification genes, and increasing pesticide tolerance (Mao et 
al. 2013; Liao et al. 2017; Wong et al. 2018; Bernklau et al. 2019). Furthermore, they both 
inhibit the replication and production of a large number of viruses (Canine Distemper Virus, 
human rhinovirus, herpes simplex virus, Japanese encephalitis virus, among others) (Graziani et 
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al. 1983; Schnitzler et al. 2010; Johari et al. 2012; González-Búrquez et al. 2018; Kwon et al. 
2019), although these tests have thus far been conducted only in mammalian systems. My current 
results do not support the hypothesis that these phytochemicals help combat IAPV infection, but 
it is difficult to rule out whether or not they activate any of the various defense mechanisms 
honey bees utilize to defend against viral infection without subsequent molecular analyses.  
 
Caffeine Investigation 
 Caffeine, a defensive alkaloid that is capable of increasing pesticide tolerance (Balieira et 
al. 2018) and reducing Nosema spore count in honey bees (Strachecka et al. 2014; Bernklau et al. 
2019), was identified by the phytochemical screening process as a potential agent for improving 
resilience against virus infection. The initial caffeine trials (Exp. 6, 7) clearly showed it 
significantly improves the survival of IAPV-inoculated honey bees, furthering our currently 
limited understanding of its physiological effects in honey bee systems. Most notably, 25 ppm, a 
concentration that bees can and do encounter in naturally occurring floral resources (Wright et al. 
2013; Couvillon et al. 2015), was sufficient to generate a beneficial effect. With its ease-of-
access and already established familiarity, caffeine has great potential for stakeholders and 
beekeeping communities as a relatively inexpensive and practical way of treating virus 
infections. However, it should be noted that, although caffeine clearly confers beneficial effects, 
it does not constitute a ‘medicine’ and therefore should not be counted on to completely clear 
viral infections. Instead, caffeine can serve as a useful instrument for furthering understanding of 
honey bee virus infections at the physiological and molecular level, while also acting as a 
potential antiviral dietary supplement.  
 The results of the caffeine dose-response curves (Exp. 8A, 8B) provide a foundation for 
understanding the range of effects of caffeine on IAPV infections. Bees in both 10,000 ppm 
treatments rapidly succumbed to the high dosages regardless of infection status, confirming the 
toxic caffeine range in bees measured by Detzel and Wink (1993) (Figures 8, 9). The 1,000-ppm 
treatments, although not as immediately lethal as the 10,000 ppm, was still detrimental for both 
inoculated and uninoculated bees and increased the mortality risk relative to all other treatments 
(except 10,000 ppm) in their respective experiments, albeit with differing magnitudes of effect 
(Tables 11, 12). At concentrations under 1,000 ppm, the results of the two experiments diverge. 
In the inoculated dose-response (Exp. 8A) 100 ppm significantly improved survivorship 
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compared to both the inoculated positive control and the 25-ppm treatment (Table 11). At 100 
ppm, caffeine is still within its natural range found in Citrus flower nectar (Kretschmar and 
Baumann 1999) and it is reasonable to expect an increased dose will amplify the antiviral effect, 
to a point. However, the results of the inoculated dose-response trial exhibited some key 
differences from those observed in the initial caffeine trials (Figure 7). First, the increase in 
virus-inoculated survivorship induced by the 25-ppm caffeine treatments in Experiments 6 and 7 
was not observed in the same treatments of Experiment 8A, despite the fact that these treatments 
shared identical physical parameters across all experiments. In fact, the 25-ppm treatment in 
Experiment 8A actually trended toward having a lower survival rate than the inoculated control, 
although this trend was ultimately not significant (Table 11). Overall, bees in both inoculated 
control and 25-ppm treatments in Experiments 6 and 7 had higher survival rates than bees in 
equivalent treatments in Experiment 8A at the same timepoints. The magnitude of effect between 
the 100-ppm treatment and the positive control in Experiment 8A was nearly identical to the 
effect measured between the 25-ppm treatment and the inoculated control of Experiment 7, 
reducing mortality risk by 13.7% and 13.5%, respectively. The 100-ppm treatment of 
Experiment 8A has essentially shifted to represent the same longevity-improving capabilities 
detected in Experiments 6 and 7. 
One hypothesis for explaining this shift in treatment effectiveness could be the result of a 
seasonal factor—the bees tested in Experiments 6 and 7 were collected and assayed in late June 
and early July of 2019 whereas Experiments 8A and 8B did not occur until mid- to late August 
of the same year. It is possible that the hives from which Experiment 8’s bees were sourced had 
already begun to experience the nutritional deficit honey bee colonies can undergo in midwestern 
agricultural landscapes. Dolezal et al. (2019b) found that hives surrounded by such landscapes 
typically suffered from a lack of forage availability, reducing colony weight and individual fat 
stores, and eventually culminating in an overall poor colony nutritional state. Moreover, they 
observed that this decline consistently began in early August, which coincides with the 
seemingly mismatched survival rates I observed in Experiment 8A. I posit that this potential 
forage dearth could have contributed to the change in caffeine-virus interaction observed in the 
inoculated bees in the caffeine dose-response trial, with the nutritionally stressed bees requiring a 
stronger dose of caffeine to achieve the same level of survivorship improvement seen earlier in 
the season. There is, of course, always the possibility that aberrations in typical honey bee 
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survival patterns can be attributed to hive genetics or intense pathogen pressure. However, the 
method used in all cage assays was purposefully designed to minimize these possibilities and 
measuring genetic differences or parasitic load after the assays was beyond the scope of this 
project.  
The bees in the control and 25-ppm treatments of the uninoculated caffeine dose-response 
assay (Exp. 8B) also yielded somewhat contrary results when compared to the same treatments 
tested in Experiments 6 and 7. The initial caffeine trials yielded no significant difference 
between the survival rates of bees in the control and 25-ppm treatments but Experiment 8B 
revealed that 25 ppm significantly decreased mortality risk by 21.6% compared to control 
(Figure 8B, Table 12). However, Experiment 8B also extends lifespan for the longest period of 
time among all caffeine trials (over twice that of Experiments 6 and 7), and it is possible that 25-
ppm caffeine does not produce a measurable effect until after 120-hpi (5 days), the point at 
which the initial caffeine trials were terminated. Alternatively, it is also possible that the 
inconsistent survival detected in Experiment 8B could have been caused by background virus 
infection. Most managed honey bee colonies are infected by a large number of different viruses, 
which can often persist throughout the hive without manifesting acute symptoms (Chen et al. 
2004; Carrillo-Tripp et al. 2016). As previously discussed, the bees used in Experiment 8B were 
collected in late August, the same point at which Varroa populations typically tend to rise 
(Rosenkranz et al. 2010), further increasing the chances of an elevated viral load not mediated by 
humans. Undetected viral infections could have depressed the survivorship of the supposedly 
uninfected control bees and the 25-ppm caffeine dose may have been just enough to ameliorate 
the viral effects without also poisoning the bees, as in the case of the 10,000 ppm treatments. 
Future experimentation examining caffeine dose-response of inoculated and uninoculated bees 
should include repeated tests across a broader temporal range to take into account any seasonal 
variation, as well as testing a narrower range of caffeine concentrations under 1,000 ppm to 
obtain a clearer image of the stratification of dosage on antiviral effect.  
Experiments 8A and 8B laid the groundwork for research in several promising directions. 
In all of the cage assays, I intentionally excluded the addition of an external protein source as a 
means of maximizing the chances of observing an effect. Pollen is a critical component of the 
bee diet, affecting many aspects of bee biology (Wright et al. 2018), including 
immunocompetence (Alaux et al. 2010), pesticide tolerance (Liao et al. 2017), and response to 
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virus infection. Dolezal et al. (2019a) showed that even the quality of pollen can influence 
mortality rates of bees infected with viruses. The exclusion of dietary pollen therefore prevents 
the accidental masking or augmentation of any potential effects incurred by phytochemical 
consumption, an observation that was shared by Palmer-Young et al. (2017b) when discussing 
the effects of phytochemicals on pathogen infection. However, following the confirmation of 
caffeine’s ameliorative qualities, subsequent studies should introduce a protein supplement to 
examine how it affects the caffeine-virus interaction.  
Lastly, RT-qPCR analysis confirmed the presence of viral infection in the expected 
groups across Experiments 6 and 7, with the inoculated treatments of both diet types having 
significantly greater viral loads than their uninoculated counterparts (Figure 9). These data are 
important in addressing the question of whether caffeine influences viral tolerance or viral 
resistance, but the conclusions that can be drawn are not definitive. The viral titers are not 
significantly different from one another within infection groups across both diet types, 
suggesting that caffeine does not actively increase viral resistance by reducing titers or hindering 
replication. However, this does not necessarily validate the presence of a tolerance mechanism, 
either. The titers are restricted to a single timepoint and thus only a snapshot of the infection 
progression is available. Moreover, I collected data only on the bees that died of infection, all of 
which had similar IAPV levels, suggesting that similar levels are linked to mortality. However, 
future experiments that perform additional sampling conducted at multiple timepoints on live and 
dead bees are necessary to understand this phenomenon. Caffeine-treated bees may be able to 
tolerate higher virus titers (although my data on bees that died of infection does not support this 
possibility), or they may be better able to resist infection by suppressing IAPV replication. In the 
case of the latter, I would predict that randomly-collected live bees from the caffeine-treated 
groups will exhibit lower IAPV levels than infected controls.  
The survivorship-enhancing effects I documented provide a useful comparison to caffeine 
tested in other insect systems, highlighting the range of coevolutionary relationships that bees 
have with the plants they use as nectar sources, relative to other insect nectarivores. Multiple 
studies have shown that caffeine possesses larvicidal properties when administered to Aedes 
mosquitoes (Laranja et al. 2003; Eastep et al. 2012), and Njoroge (dissertation in progress) 
demonstrated that concentrations similar to those that improved IAPV-inoculated bee 
survivorship (100, 200 ppm) actually significantly reduced the lifespan of A. albopictus. Eastep 
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et al. (2012) found that caffeine did not significantly alter the titers of the La Crosse virus (a 
mosquito-borne virus capable of causing encephalitis in humans) in A. albopictus, a result 
similar to that of IAPV measured in my experiments.  
Eventually, these caffeine treatments results could be used to scale the project up to semi-
field conditions to test effects on whole colonies and use gene expression measurements to 
characterize the genes responsible for resistance to viral pathogens. Ascertaining the full scope of 
caffeine’s antiviral qualities can help craft recommendations for reducing virus pressure in 
managed honey bee colonies, provide understanding of basic mechanisms by which bees reduce 
pathogen infection, and enrich the understanding of the coevolution between plant nectar sources 
and pollinators.  
 
Conclusion  
 Through a series of screening experiments, I have shown that p-coumaric acid, quercetin, 
and encapsulated thymol and carvacrol do not have a significant effect on honey bee 
survivorship during IAPV infection. While this finding is not consistent with the hypothesis that 
these chemicals provide protection against virus infection, it is important to note that the high-
throughput bioassay screens I performed does not account for all possible scenarios. Most 
notably, I have demonstrated that caffeine consumed at a naturally occurring level can 
significantly increase honey bee survival when they are infected with IAPV. Furthermore, I have 
expanded upon my initial caffeine results by establishing caffeine dose-response curves in honey 
bees to determine the scope of caffeine’s effect at different concentrations with or without viral 
infection. These dose-response curves show that 100 ppm caffeine has a similar effect to that of 
25 ppm in IAPV-inoculated bees but only 25 ppm improves survivorship relative to controls fed 
unamended sucrose in the absence of IAPV inoculation. To attain a more granular understanding 
of caffeine’s effects on virus infection, I would recommend future research along four additional 
pathways: (1) testing a narrower dose range under 1,000 ppm across a wider temporal range, (2) 
including dietary pollen in regular test diet, (3) increasing bee sampling for a clearer molecular 
picture of virus propagation rates, and (4) eventually expanding into testing additional viruses, 
such as the ubiquitous DWV. Exploration into these areas can both allow for a better grasp of 
how caffeine interacts with virus and improve comprehension of virus-phytochemical 
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